City File: High hopes

Click to follow
MEDEVA, the pharmaceuticals group, has high hopes for methylphenidate, its amphetamine drug used to treat hyperactive children. Increased demand has given Medeva greater leverage in negotiating production quotas with the US authorities. The drug, which is highly cash-generative with gross margins in excess of 80 per cent, is thought to be taking market share from Ciba Geigy, the only other manufacturer.